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To determine the optimal drug and light dose for prostate ablation using 
WST11 (TOOKAD® Soluble) for Vascular Targeted Photodynamic (VTP) 
therapy in men with low-risk prostate cancer. 
 
Patients and methods 
 
Forty men received a single dose of 2, 4 or 6mg/kg WST11 activated by 
200J/cm light at 753 nm. WST-11 was given as a 10 minute intravenous 
infusion. The light dose was delivered using cylindrical diffusing fibres 
within hollow plastic needles positioned in the prostate using transrectal 
ultrasound scan (TRUS) guidance and a brachytherapy template. Magnetic 
resonance imaging (MRI) was used to assess treatment effect at 7 days, 
with assessment of urinary function (International Prostate Symptom Score 
[IPSS]), sexual function (International Index of Erectile Function [IIEF]) 
and adverse events at 7 days, 1, 3 and 6 months. TRUS guided biopsy was 




Thirty-nine of 40 treated men completed follow up. The Day 7 MRI showed 
maximal treatment effect (95% of the planned treatment volume) in men 
who had a WST11 dose of 4mg/kg, light dose of 200J/cm and light density 
index (LDI) of >1. In the 12 men treated with these parameters, the 
negative biopsy rate was 10/12 (83%) at 6 months, compared to 45% 
(10/26) for the men who had either different drug doses (n=10), or an LDI 
of <1 (n=16). Transient urinary symptoms were seen in the majority of 
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4mg/kg TOOKAD® Soluble activated by 753nm light at a dose of 200J/cm 
and an LDI >1 resulted in treatment effect in 95% of the planned 
treatment volume and a negative biopsy rate at 6 months of 83% in a 





Currently, men who are diagnosed with early prostate cancer face the 
dilemma of whether to undergo active surveillance or have treatment directed 
to the whole prostate, with surgery or radiotherapy [1, 2]. Active surveillance 
involves repeated biopsies and frequent prostate-specific antigen (PSA) 
testing, often results in anxiety, and cross-over to active therapy occurs with 
or without evidence of progression [3]. Whole gland treatment is associated 
with a known set of side-effects, that most men wish to avoid [4]. The 
increasing precision of modern diagnostics is permitting a more refined 
characterisation of risk and has introduced the relatively novel attribute of 
tumour location [5,6]. This transition has permitted the substitution of an 
anatomical target for therapy – in other words the contour of the prostate – to 
one that is defined by the location and burden of the tumour.  The result is 
tissue preserving or focal therapy [7], an approach that has proved beneficial 
in most other solid organs.   
 
Vascular-targeted photodynamic therapy (VTP) uses a photosensitising agent 
(WST11, TOOKAD® Soluble), activated by 753nm light to generate reactive 
oxygen species (ROS) within blood vessels. These ROS lead to vessel 
thrombosis and subsequent tissue necrosis around the light delivery fibre. The 
bacteriochlorophyll derivatives are a novel generation of light-activated 
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(padoporfin; palladium bacteriopheophorbide) and its water-soluble derivative 
WST11 (padeliporﬁn; palladium bacteriopheophorbide monolysotaurine). Pre-
clinical studies have demonstrated their efficacy for the ablation of prostatic 
tissue [8]. Phase II studies demonstrated that WST09 effectively produced 
ablation in targeted volumes of prostate tissue. However, intraoperative 
hypotension occurred in association with cardiovascular effects that were 
thought to be linked to the solubilizing excipient Cremophor® [9]. In order to 
avoid these side effects, the hydrophilic derivative WST11 was developed, 
which is soluble in aqueous solutions, so that Cremophor®  is not required 
[10]. Preclinical studies in several animal models have shown that treatment 
with WST11 leads to occlusion of the entire tumour vasculature within a few 
minutes of treatment, leading to tumour ablation [11, 12, 13]. 
 
The present paper reports the findings from a Phase II, prospective, 
multicentre, open-label, single intravenous (IV) dose study of WST11- VTP, 
which was designed to determine the optimal drug concentration and light 
dose parameters to achieve prostate ablation in men with early prostate 
cancer. The primary efficacy criteria were the histological assessment of a 
6-month biopsy, and assessment of volume of hypoperfusion on gadolinium 
enhanced magnetic resonance imaging (MRI) scan at 7 days. Safety and 
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Patients and methods 
 
Patients 
Men (>18 years of age) diagnosed with low-risk prostate cancer, who were 
suitable for active surveillance, were invited to take part in the study. The 
main exclusion criteria were: Prior or current treatment for their cancer, 
including hormonal manipulation (excluding 5-alpha reductase inhibitors) or 
androgen supplements in the last 6 months, radiation therapy, chemotherapy, 
or trans-urethral resection of the prostate and the use of any photosensitising 
medication for 1 month before and 1 week after the VTP procedure. In men 
diagnosed by transrectal ultrasound scan (TRUS) guided biopsy, the 
histological entry criterion was limited to Gleason pattern 3+3. For men 
diagnosed by transperineal template guided biopsy, secondary Gleason 
pattern 4 was permitted provided that it was low burden (<3 cores positive per 
lobe and </=3mm maximum cancer core length). No other restrictions were 
placed on the number of positive cores present at baseline. The upper limit of 
PSA prior to consent was 10ng/ml, with a maximum clinical stage of T2b 
(radiological stage T2c acceptable).  
 
Ethics statement 
The study was conducted within 9 university hospital centres in Europe 
(France, the Netherlands and United Kingdom) and Canada. 
 
The protocol, all protocol amendments, the proposed Patient Informed 
Consent Document were submitted to the following Independent Ethics 
Committees or Institutional Review Boards for approval. All patients gave 




This was a multicentre, phase II, open-label, single IV dose escalation, 6-
month, clinical trial, designed to determine the optimal treatment conditions 
necessary to achieve prostate cancer ablation. Patients were followed for 
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months and 6 months after the VTP procedure, and a prostate biopsy was 
undertaken at 6 months post-procedure.  
 
The trial was registered at ClinicalTrials.gov (NCT00975429) and in the 
EudraCT register (2008-000876-26).  
 
VTP procedure 
WST11- VTP treatment comprised a single IV administration of WST11 
(TOOKAD® Soluble; STEBA Biotech, L-2613 Luxembourg) at a dose of 2, 4 or 
6mg/kg, using 753nm laser light at a fixed power (150mW/cm) and energy 
(200J/cm) delivered through transperineal interstitial optical fibres positioned 
in the prostate. The rate of infusion varied according to body weight since the 
duration of the infusion remained constant (10 minutes). 
 
Preclinical data had shown predictable ablation volumes using 2mg/kg of 
WST11 with a light energy dose of 200J/cm [15]. These were the treatment 
parameters for the first 3 men in the study. The drug dose escalation plan 
comprised an increase to 4 and 6mg/kg, contingent on the effects on prior 
patients. The decision to escalate the dose was based on the volume of 
hypoperfusion (treatment effect) on the Day 7 MRI and any AEs reported to 
the Data Safety Monitoring Board.  
 
The procedure was performed under general anaesthesia. The procedure has 
been previously described in detail [9, 10]. A transperineal template (Mick 
Radio-Nuclear Instruments, Inc, USA) was used to position hollow, 
transparent, plastic brachytherapy-like catheters (Best Medical International, 
Inc, USA, model 1117-20 and Medlight SA, Switzerland, model iCAT-2.0-200) 
into the prostate, using TRUS image guidance, in accordance with a 
previously devised MRI-based treatment plan. Cylindrically diffusing optical 
fibres (Medlight SA, Switzerland, model RD and CeramOptec GMBH, 
Germany, model CD) were inserted into the catheters. The number and 
positioning of the fibres were adapted to each patient in order to obtain zonal 
to sub-total destruction of the prostate areas of interest. Examples of the 
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gland axial plan after gadolinium injection) are shown in Figure 1. The 
decision on which plan to use was taken by a Treatment Planning Guidance 
Team, comprising the radiologist, who did the treatment planning based on 
the pre-treatment MRI, the Principal Investigator, and the consultant urologist. 
The Team’s decision was based on the number of positive cores and the 
extent and location of disease (eg, unilateral or bilateral disease), but 
depended also on the dose escalation scheme at the time an individual 
patient was enrolled.  
 
The length of diffusing fibre varied between 1 and 4cm, in 0.5cm increments; 
the length was chosen to allow a 5-mm safety margin between the end of the 
diffuser and the base, the apex and the capsule of the prostate, unless a 
larger safety margin was deemed necessary, such as at the start of a new 
drug dose group. Laser light at 753nm was delivered to the prostate, using a 
multichannel diode laser (V-Gen Electro Optics Ltd, Israel, model 8CH-753 
Mk II). A maximum of 2 lasers with 8 channels (16 fibres in total) were used 
per patient. Light monitoring was done by the use of optical detector fibres 
(Medlight SA, Switzerland, model IP) in the prostate, rectum and urethra, 
connected to a continuously recording light dosimeter (V-Gen, model 8CH-
PDT-DOS-1). 
 
The single WST11 IV dose was a 10-minute infusion, conducted using 
automatic syringes, through a fast flow peripheral line (antecubital catheter) or 
a central line. This was followed by continuous illumination of the prostate 
gland through optical fibres for 22 minutes and 15 seconds in order to activate 
the WST11. Light delivery was initiated at the end of the WST11 infusion in 
order to coincide with the peak serum concentration of WST11. The total light 
dose varied according to the length and number of optical diffusing fibres. 
This phase was precisely monitored by continuous clinical surveillance and 
was stopped in the event of occurrence of a significant AE. The total duration 
of the whole procedure was about 2 hours (including anaesthesia, fibre 
placement and illumination with the laser light). At the end of the illumination, 
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A urinary catheter was left in situ until the next morning. The patient was 
required to wear protective eye wear and stay in low level light for the first 
hours after the treatment. 
 
Efficacy and Safety Criteria 
The primary efficacy criterion was the result of a 12-core prostate biopsy, 
6 months after VTP. Success was defined as a negative biopsy in the treated 
lobe(s). 
 
The secondary efficacy criterion was the volume of VTP effect assessed as 
the volume of intraprostatic hypoperfusion on the Day 7 MRI.  The MRI 
protocol used a pelvic phased array coil with a 1.5T MRI, although the 
manufacturer varied between centres.  
 
Adverse Events (AEs) were recorded and laboratory evaluations were 
performed periodically during the 6-month follow-up period; AEs were coded 
using the Medical Dictionary of Regulatory Activities (MedDRA), version 12.0. 
The patients also underwent 12-lead electrocardiograms (ECGs) at baseline, 
during the VTP procedure and peri-operatively. Toxicities were graded 
according to the National Cancer Institute’s Common Terminology Criteria for 
AEs (CTCAE), version 3.0. The relationship of the AEs was assessed with 
respect both to the study treatment and to the technical procedure of the VTP. 
Urinary and erectile function prior to VTP, and at 1, 3 and 6 months 
post−treatment, were assessed using the International Prostate Symptom 
Score (IPSS) and International Index of Erectile Function (IIEF-5) quality of 
life questionnaires, respectively. 
 
Statistical Methods 
Descriptive statistics (n, mean, standard deviation (SD), median, minimum 
and maximum) were calculated for quantitative variables; frequency count by 
category was given for qualitative variables. Confidence intervals were given 
where appropriate. If not otherwise stated, all statistical tests were 2-sided 











This article is protected by copyright. All rights reserved. 
The only statistical inference performed was the 1-sided binomial exact test 
for the proportion of patients with negative biopsy assessment at Month 6. 
This study served to generate hypotheses on the primary efficacy objective for 
a future phase III clinical study. A significant difference between the proportion 
under the null hypothesis and the alternative of at least 25% was seen as 






Forty-two men were enrolled in the study with 4 excluded from the final 
efficacy analysis (Figure 2). The baseline characteristics of the 42 enrolled 
men are shown in Table 1. Two patients underwent anaesthesia for the 
procedure, but did not receive the drug or light dose: one patient due to a 
rectal abnormality which precluded satisfactory ultrasound probe placement, 
and another due to ECG changes suspicious for ischaemia which were seen 
after the start of the anaesthesia. Two additional patients underwent the full 
VTP procedure, but could not be evaluated for efficacy: one man had the 
incorrect lobe treated and the other was staged as T3a at Month 6, which on 
central radiologist review was confirmed as being present and missed prior to 
VTP. The patient in whom the wrong lobe was treated was retreated in the 
correct lobe after the Month 6 biopsy.  
 
Of the remaining 38 men, 3 men had significant protocol deviations (laser 
malfunction at the time of treatment, n=2) and administration of an ultrasound 
contrast agent at the time of the procedure (n=1).  
 
Three patients were treated with WST11 at a dose of 2mg/kg, and 2 patients 
received the 6mg/kg dose. In the 3 patients treated at the lowest dose, little 
effect was seen on the Day 7 MRI scans and therefore this dose was deemed 
to be sub-optimal and no further patients were enrolled at 2mg/kg. The 
6mg/kg dose was deemed not suitable for smaller glands, as the treatment 
effect with 3 fibres appeared to be difficult to maintain within the boundaries of 
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was evaluated in study PCM203, where it did not result in larger volumes of 
effect than 4mg/kg. .   
 
Thus, the majority of patients (n=33) were dosed at 4mg/kg. All patients who 
received the WST11 dose were treated with a light energy of 200J/cm, except 
for 2 patients who received an energy dose of 350J/cm due to a laser 
malfunction, and were excluded from the final efficacy analysis.  
 
In total, 28 men had a drug dose of 4mg/kg, a light dose of 200J/cm and a 
minimum of 3 light fibres. An exploratory analysis of these men showed that 
the light dose per volume of prostate was an important determinant of both 
treatment effect on contrast enhanced MRI at 1 week, and of 6-month biopsy 




In the 4mg/kg group, 12 men had an LDI of >1, and 16 men an LDI of <1 




One patient declined the 6-month biopsy, so 37 biopsies were available for 
the analysis of the primary efficacy criterion and 38 MRI scans were available 
for the secondary efficacy criterion.  
 
Of those men who could be evaluated (n=37), 20 had a negative 6-month 
biopsy (53%), while of those men in the optimal dose-energy group (n=28), 15 
had a negative 6-month biopsy (54%) (Table 2). However, when the 
assessment was limited to men with the optimal treatment conditions (4mg/kg, 
200J/cm, LDI >1), the percentage having a negative biopsy increased to 83% 
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Histopathological analysis of the 6-month biopsies showed that fibrosis was 
the most frequent histopathological finding after VTP. There were no foci of 
prostate cancer found within areas of fibrosis.  
 
Gadolinium-enhanced MRI at 1 week 
 
The prostate volume was seen to increase between baseline and 7 days from 
a mean of 50.7mL to 63.9mL across the 38 men who underwent Day 7 MRI. 
This swelling reduced over time, and, combined with fibrosis showed a 
reduction to a mean volume of 41.8mL at 3 months (n=36), and 40mL at 
6 months (n=33).  
The volume of treatment effect was defined as the volume of hypoperfusion at 
Day 7 divided by the mean of the intended treatment volume at baseline and 
at 7 days. 
 
In the 38 evaluable men at Day 7, the mean percentage treatment effect 
(treatment volume/whole prostate volume) was 38%. In men in the 4mg/kg 
group (n=33), the mean treatment effect was 42%. The majority of these men 
had had treatment in one lobe only.  
 
In an exploratory analysis of the treated lobe only, the 12 men of the 4mg/kg 
group with an LDI >1 had a mean treatment volume effect (treatment 
effect/lobe volume) of 95% versus 59% (p<0.01) in those with an LDI <1. “ 
 
The correlation between the LDI and the volume of effect is shown in Figure 
3.  
 
Extraprostatic treatment effect (hypoperfusion outside of the prostate) was 
observed in 18 of 38 men; in all cases this resolved on follow-up imaging, and 
was not associated with any clinically evident damage to adjacent organs, 
fistula or incontinence.  
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34 patients (81%) reported a total of 131 AEs. All AEs were mild or moderate 
in intensity, with the exception of a melanoma in one of the subjects, which 
occurred after a number of months. This was considered severe but unrelated 
to the either the study drug or the procedure.  
 
28/42 patients (66.7%) experienced at least 1 AE related to the technical 
procedure and 14 patients (33.3%) experienced at least 1 AE related to the 
study drug. The most common AEs related to the technical procedure were 
coded to the Reproductive System and Breast Disorders system organ class 
(SOC) (haematospermia, n=5; erectile dysfunction, n=4; and perineal pain, 
n=4) and Renal and Urinary Disorders SOC (dysuria, n=9; hematuria, n=8; 
and transient urinary retention, n=2). Due to the small number of patients 
treated at 2 and 6 mg/kg, no analysis can be made on the difference in the 
level of side effects observed between the treatment doses. 
 
Five patients experienced SAEs of which 3 were related to the technical 
procedure. Two patients had large extraprostatic necrosis caused by an 
excessive light dose due to a calibration error; corrective measures were 
taken immediately to ensure it did not reoccur and both patients recovered 
without sequelae. One patient had pelvic pain which prolonged hospitalisation 
by 1 day and was due to the technical procedure. The 2 other SAEs (deep 
vein thrombosis at 4 months post-procedure and dysuria secondary to a 
herpetic eruption at 3 days post-procedure) were considered unlikely to be 
related to the treatment.  
 
Of the 40 patients who received the complete VTP procedure, none withdrew 
due to AEs. 
 
An analysis of the paper ECG recordings was performed by CardiaBase, an 
ECG core lab. The results indicated a marked prolongation of the Fridericia-
corrected QT (QTcF) interval after the induction of anaesthesia. However, as 
no further prolongation of the QTcF interval was observed after the injection of 
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There were some minor changes in the biochemical parameters including 
transient elevation of hepatic enzymes in 12 men in the immediate 
postoperative period. This had no clinical consequences, and resolved without 
specific treatment. The elevation in hepatic enzymes was deemed by the 
investigator related to anaesthesia, as it is not unusual to observe such an 
increase after a general anaesthetic. No long-term consequences were 
expected as these elevations were always mild (mostly <2 x upper limit of 
normal) and transient. 
 
The safety data of the 40 patients have been reviewed in detail by the Data 
Safety Monitoring Board. No significant safety issue was identified and the 
general tolerability of the procedure was considered good.  
 
Quality of Life Questionnaires 
Questionnaires were evaluable for 34 patients at baseline and Month 6. 
 
IPSS questionnaire 
For all 34 evaluable men, the mean IPSS score for questions 1-7 decreased 
from 7.3 at baseline, to 6.6 (10.1% mean change) at Month 1, 5.4 (-31.7%) at 
Month 3 and 5.1 (-17.3%) at Month 6. Of the 29 evaluable men in the optimal 
treatment group (4mg/kg), mean IPSS score for questions 1-7 decreased from 
6.3 at baseline, to 5.6 (15.2% mean change) at Month 1, 3.7 (-36.7%) at 
Month 3, and 3.8 (-18.1%) at Month 6. 
 
For the quality of life domain of the IPSS score (Question ‘How would you feel 
if your urinary symptoms stayed the same for the rest of your life?’), where a 
higher score indicates greater unhappiness with symptoms, there was a 
significant fall in the QoL score from 2.1 to 1.3 from baseline 
to Month 6 (p<0.013). The results were comparable between all patients and 
those receiving the optimal treatment. 
 
IIEF-5 Questionnaire 
For all 34 evaluable men, the mean baseline score was 17.7, falling to 13.8 at 
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statistical difference between baseline and Month 3 or Month 6. Of the 29 
evaluable men in the optimal (4mg/kg) treatment group, the mean baseline 
score was 18.0, falling to 13.3 at Month 1, then rising to 16.4 at Month 3, and 
17.0 at Month 6. Of the 25 patients who had a baseline score of over 15, 4 
patients (27%) had an IIEF decrease of more than 10 points at Month 6. Over 
the 6-month period of the study, 4 patients developed de novo erectile 






TOOKAD® Soluble VTP exhibits many of the desired attributes of a minimally 
invasive, well-tolerated procedure that can be targeted to a pre-determined 
volume of prostate tissue and administered in an ambulatory setting as a one-
off procedure.  This study has contributed to defining the optimal treatment 
conditions to achieve predictable ablation volumes within the prostate and so 
provide a method by which clinicians can selectively ablate target volumes of 
tissue.  
 
More specifically, biopsy data, post-treatment MRI outputs and analysis of the 
safety data indicate that 4mg/kg WST11, 200J/cm energy and an LDI >1 are 
probably optimal treatment conditions for prostate ablation using the VTP 
procedure. In addition the Day-7 MRI result proved to be a good predictor of 
the 6-month biopsy result, with a mean 95% treatment effect on Day-7 MRI 
correlating with an 83% negative biopsy rate in men receiving the optimal 
treatment parameters, compared to a mean treatment effect of 58% and a 
negative biopsy rate of 31% in the 16 men who received 4mg/kg WST11 with 
an LDI of <1. This correlation is supported by both preclinical data [14] and 
those from the post-radiotherapy prostate [9]. 
 
In terms of tolerability and safety, WST11 fared well. No cases of hypotension 
were reported, which had been a concern with the previous formulation 
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from 1 severe case (neoplasm) in the 4mg/kg group, which was considered 
unrelated to the study medication or procedure. There were 5 SAEs, all in the 
4mg/kg group. None were considered related to the study drug, but 3 of the 
5 were considered to be related to the study procedure: 2 necrosis events 
caused by excessive illumination due to device malfunction and 1 of pelvic 
pain, which was considered serious as it prolonged hospitalisation by 1 day.  
 
Additional unexpected benefits were also recorded.  The cohort exhibited a 
fall in IPSS score that was accompanied by a slight improvement in the quality 
of life.  Erectile function was difficult to assess given that many of the subjects 
recorded poor or absent baseline function.  Overall there was mild 
deterioration.  
 
These results need to be considered in the light of some inevitable 
methodological limitations. First, the number of patients was small as this was 
an early phase II trial. As it was a dose escalation study, the results of doses 
other than 4mg/kg were confined to very small samples. A follow-on study 
(PCM 203) was designed to explore the use of 4mg/kg WST11 and an LDI of 
1 in a larger study population. Following completion of PCM 203 a European 
multicenter phase III study randomizing men to WST11 VTP or active 
surveillance was set up and has now completed recruitment and 
randomization of 400 men.  
 
Second, due to the limited sensitivity of TRUS biopsy, a negative biopsy at 
6 months post-VTP procedure does not necessarily confirm the absence of 
tumour. In the context of low-risk prostate cancer on standard TRUS biopsy, 1 
in 4 men may have no cancer found on repeat TRUS, although 1 in 4 may be 
upgraded or upstaged [15]. We considered the use of transperineal template 
guided biopsy both prior to and following VTP, but decided that the 
requirement for 3 general anaesthetics in the 6-month study would be too 
great a burden for the patient. Men who had a template biopsy at baseline 
(5/41, 12%) were those enrolled in centres with a high volume of men having 
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Third, this study had a short follow-up of 6 months, and longer term 
histological results and patient-reported outcomes are going to be needed in 
order to establish oncological efficacy.  
 
The attributes of the VTP procedure are very different to existing focal therapy 
platforms that rely principally on generating extremes of temperature in order 
to induce coagulative necrosis.  These energy sources require an iterative 
and responsive mode of delivery that is surgeon-driven and is challenging to 
teach and to learn [16]. WST11 VTP can be planned in advance and the 
execution is limited to the placement of needles within a sector of the prostate 
under ultrasound control  - a skill that is widely held and easily taught.  This, 
together with the opportunity to be amenable to quality control is a welcome 
attribute.    
 
This study has permitted a standardisation of the procedure, which is an 
essential step in the evaluation of any health technologies. It has permitted 
the design and subsequent approval of a Phase III study in Europe 




This study has shown that the optimal drug dose, light dose and light density 
index for prostate ablation using TOOKAD® Soluble are 4mg/kg WST11 
activated by 753nm light at a dose of 200J/cm and a light density index of >1. 
These parameters applied in a group of 12 men resulted in treatment effect in 
95% of the planned treatment volume and a negative biopsy rate at 6 months 
of 83%.   
 
Further work to assess this within a European phase III randomized controlled 
trial comparing WST11 VTP to active surveillance is ongoing, with recruitment 
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Figure 1 Schematic Diagram of Treatment Plans and Corresponding 
Day 7 MRI Results 
The 3 treatment plans for focal therapy of low-risk, early stage prostate cancer 
by WST-mediated VTP therapy, which were considered by the Treatment 
Planning Guidance Committee, are displayed. The possible different fibre 
configurations used are illustrated. 
 
The red circles indicate the possible location of the fibres; the blue circle 
indicates the position of the urethra in the prostate gland. 
 
The corresponding magnetic resonance imagining (MRI) scans, taken on 
Day 7, are displayed underneath. 
 
Figure 2 Flow Chart Showing Participants in the Study 
The flow chart summarises the participants in the study and the numbers of 
patients that fell into the different treatment groups, based on WST11 dose 
(2, 4, or 6mg/kg) and light energy (200J/cm) administered and the number of 
interstitial optical fibres through which the infusion was delivered. 
Four patient populations were defined: 1) Efficacy Evaluable Population 
included all patients who received the complete VTP procedure, excluding 
major protocol deviations identified during a blinded review before database 
lock; 2) Optimal Dose-Energy Population (ODEP) included all patients who 
received a 4mg/kg WST11 dose, 200J/cm energy dose, with at least 3 fibres 
and no major protocol deviations; 3) Optimal Treatment Conditions Population 
included patients from the ODEP that had an LDI equal or superior to the 
optimal LDI found during the exploratory analysis; and d) Safety Population 
included all patients who went through any part of the VTP procedure. 
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Figure 3 Correlation Between LDI Delivered and Necrosis Volume on 
Day 7 
A positive correlation can be seen between the volume of necrosis measured 
on the Day 7 magnetic resonance images and the Light Density Index (LDI) 
delivered. 
 
The red line is the regression line, and the blue lines are the confidence 




















































Table 1 Patient Demographics and Other Baseline Characteristics (Safety Population) 
 WST11 Dose Group  
 Mean ± SD 
 2 mg/kg 4 mg/kg 6 mg/kg All doses 
 N=3 N=37 N=2 N=42 
Age at enrolment (years) 63.5 ± 5.5 63.7 ± 5.5 63.4 ± 0.3 63.9 + 5.3 
Transrectal biopsy (n=1) (n=34) 1 (n=2) (n=37) 
Gleason score on TRUS 
biopsy 
3 + 3  (n = 1) 3 + 3 (n = 34) 3 + 3 = 2 
  
3 + 3 (n = 37) 
Total no. cores analysed 12 12.8 ± 2.8 13.0 ± 1.4 12.8 ± 2.7 
Number of positive cores 3 2.3 ± 1.1 1.0 ± 0.0 2.2 ± 1.1 
Transperineal biopsy (n=2) (n=3) (n=0) (n=5) 
Gleason score on 
transperineal biopsy 
3 + 3 (n = 2) 3 + 3 (n = 2) 
3 + 4 (n = 1) 
N/A 3 + 3 (n = 4) 
3 + 4 (n = 1) 
Total no. cores analysed 85.5 ± 16.3 58.7 ± 18.0 - 69.4 ± 21.1 
Number of positive cores 1 ± 0.0 3 ± 1.7 - 2.2 ± 1.6 
Clinical staging, n (%)     
T1 2 34 2 38 (90.5) 
T2 1 3 0 4 (9.5) 












Table 2 Biopsy Results at Month 6 According to Analysis Group (All Doses Combined) 
Analysis Group No. 
Patients  
No. (%) of Patients with 
Positive Biopsies 
No. (%) of Patients with 
Negative Biopsies  
p value  
(compared to 0.4*) 
 
Men who received the complete VTP 





17 (45) 20 (53) - 
Patients who had the complete VTP 
procedure at 4mg/kg with at least 3 fibres 
and no major protocol deviations
 
28 13 (46.4) 15 (53.6) 0.10 
Men who had 4mg/kg but LDI <1 16 11 (69) 5 (31.3)   
Men who had optimal treatment conditions 
(4mg/kg, 200J/cm, LDI>1). 
 
12 2 (16.7) 10 (83.3) 0.003 
* the p value assess the probability of the observed results happening by chance if the null hypothesis (that the treatment has no 
effect) were true. The proportion of men who would have a negative confirmatory biopsy in the absence of treatment was taken as 
40%, to reflect the proportions of men on active surveillance having a negative second biopsy after an initial positive biopsy 
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